CEO Pay Mostly Up In India In Year Of C-Suite Exits
Executive Summary
Most CEOs/MDs at leading listed foreign and domestic drug firms in India took home bigger pay packages in 2021-22, a period that also saw several top-level exits including at Abbott, Pfizer and Sanofi. Scrip examines some of the wider trends around executive compensation.
You may also be interested in...
India CEO Pay: Up, Up For Most, Eye On Gender Pay Gap As Women Execs Rise
C-suite remuneration at leading listed foreign and domestic drug firms in India rose in double digits for the most part in 2022-23, data compiled by Scrip show. While MDs/CEOs at domestic firms continue to take home sizeably higher earnings, the arrival of women leaders at the helm in some foreign firms puts the spotlight on gender pay parity.
Big Pharma Restructures Commercial Teams In India
More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.
Big Pharma Rescripts India Playbook
Big pharma appears to be resetting operations in India fueling some concerns of waning interest. In Vivo looks at what the realignment means or doesn’t.